目的：通过文献荟萃分析评价利妥昔单抗治疗中重度甲状腺相关眼病的疗效。

方法：检索中国知网(CNKI)、万方、维普、中国生物医学、PubMed、Web of Science、OVID、Corhone Library、ClinicalTrial.gov等数据库从建库至2019-12-31发表的关于利妥昔单抗治疗中重度甲状腺相关眼病的临床研究。以治疗前后甲状腺相关眼病的临床活动评分为疗效的主要判定指标。将检索到的文献应用RevMan 5.3统计学软件进行分析。

结果：纳入了6项研究61例患者，其中2项为随机对照试验，4项为队列研究。Meta分析显示，应用利妥昔单抗治疗中重度甲状腺相关眼病，可使患者的临床活动评分显著降低\〖SMD=-5.04，95%CI(-7.08～-3.01)，P<0.00001\〗。

结论：利妥昔单抗可使中重度甲状腺相关眼病患者的临床活动评分显著下降，对疾病的控制有良好效果。

METHODS: Databases such as CNKI, Wanfang, Weipu, China Biomedical, PubMed, Web of Science, OVID, Cochrane Library, and ClinicalTrial.gov were searched. From the establishment of the database to December 31, 2019 on rituximab clinical studies on the treatment of thyroid associated ophthalmopathy. The clinical activity score of thyroid associated ophthalmopathy before and after treatment was used as the main judgment index of curative effect. The retrieved clinical studies were analyzed using RevMan 5.3 statistical software.

RESULTS: Six studies were included, two were randomized controlled trials, and four were cohort studies. Meta analysis showed that the application of rituximab in the treatment of moderate to severe thyroid associated ophthalmopathy can significantly reduce the clinical activity score of patients, and has statistical significance \〖SMD=-5.04, 95% CI(-7.08 to -3.01), P<0.00001\〗.

CONCLUSION: Rituximab can significantly reduce the clinical activity score of patients with moderate to severe thyroid associated ophthalmopathy, and has a good effect on disease control.